Stemtech CORP

Stemtech Corporation reports the resignation of CFO James Cardwell and the appointment of Shrilakshmi Vadlapatla as the new CFO, effective April 11, 2025.

Stemtech Corporation has ended its pursuit of a reverse takeover of Eevia Health Plc and is now concentrating on a merger with Viago, aiming for a listing on the Swedish MTF Nordic SME.

Stemtech Corporation is set to merge with Seacret Direct and pursue a reverse takeover of Eevia Health, aiming to create a vertically integrated global health and wellness leader.

Stemtech Corporation has entered into a merger agreement with Seacret Direct/Viago, valuing the acquisition at $32.5 million in Stemtech shares.

Stemtech Corporation has replaced Turner Stone LLP with Bush & Associates CPA as its independent registered public accounting firm, effective August 15, 2024.

Stemtech Corporation reported a significant net sales decline and recurring losses, raising substantial doubt about its ability to continue as a going concern, despite cost-cutting and strategic expansion efforts.

Stemtech Corporation reported a reduced net loss in Q2 2025 despite a significant drop in net sales, driven by aggressive cost management and a strategic recalibration.

Stemtech Corporation reported a higher net loss for Q1 2025 compared to the prior year, driven by decreased net sales despite significant reductions in operating and interest expenses, while facing substantial doubt about its ability to continue as a going concern.

Stemtech Corporation's Q3 2024 results show a slight increase in net sales but a significant net loss, highlighting ongoing challenges and restructuring efforts.

Stemtech Corporation's Q2 2024 results show a revenue increase compared to the same period last year, but the company continues to face significant financial challenges and operating losses.

Stemtech Corporation's Q1 2024 results show a rise in net sales and a decrease in operating loss compared to the same period last year, alongside ongoing efforts to manage debt and expand its business.

Stemtech Corporation reports a significant decline in annual revenue and a widening net loss for fiscal year 2025 amid supply chain disruptions and liquidity constraints.

Stemtech Corporation's latest 10-K filing reveals a reduced net loss and improved operating cash flow for 2024, yet highlights significant financial challenges including a substantial accumulated deficit, working capital deficiency, and material weaknesses in internal controls, raising substantial doubt about its ability to continue as a going concern.

Stemtech Corporation's 2023 annual report reveals a slight increase in net sales, a reduction in operating expenses, and a significant decrease in net loss compared to the previous year, alongside strategic moves to expand its market presence.

Benjamin Nathaniel Kaplan, a Director and 10% Owner of Stemtech Corp, has reported the sale of 1,000,000 shares of common stock at $0.03 per share.

Charles Stuart Arnold, a director of Stemtech Corp, reported acquiring 25,000 shares of common stock at $0.05 per share on July 26, 2024.

Mindshare Holdings, a less than 5% shareholder of Stemtech Corp, disposed of 25,000 shares of common stock at $0.0641 per share on April 19, 2024.